-
Barouch D H, Nabel G J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1[J]. Hum Gene Ther, 2005, 16(2): 149-156. doi: 10.1089/hum.2005.16.149
-
Burton D R, Desrosiers R C, Doms R W. HIV vaccine design and the neutralizing antibody problem[J]. Nat Immunol, 2004, 5(3): 233-236. doi: 10.1038/ni0304-233
-
Egan M A, Megati S. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice[J]. Vaccine, 2006, 24(21): 4510-4523. doi: 10.1016/j.vaccine.2005.08.024
-
Garber D A, Silvestri G, Feinberg M B. Prospects for an AIDS vaccine: three big questions, no easy answers[J]. Lancet Infect Dis, 2004, 4(7): 397-413. doi: 10.1016/S1473-3099(04)01056-4
-
Girard M P, Osmanov S K, Kieny M P. A review of vaccine research and development: the human immu-nodeficiency virus (HIV)[J]. Vaccine, 2006, 24(19): 4062-4081. doi: 10.1016/j.vaccine.2006.02.031
-
Koff W C, Johnson P R, Watkins D I. HIV vaccine design: insights from live attenuated SIV vaccines[J]. Nat Immunol, 2006, 7(1): 19-23. doi: 10.1038/ni1296
-
Hinkula J. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity[J]. Expert Rev Vaccines, 2007, 6(2): 203-212. doi: 10.1586/14760584.6.2.203
-
Johnston M I, Fauci A S. An HIV vaccine--evolving concepts[J]. N Engl J Med, 2007, 356(20): 2073-2081. doi: 10.1056/NEJMra066267
-
Kim D, Elizaga M, Duerr A. HIV vaccine efficacy trials: towards the future of HIV prevention[J]. Infect Dis Clin North Am, 2007, 21(1): 201-217. doi: 10.1016/j.idc.2007.01.006
-
Koff W C, Johnson P R, Watkins D I, 20 06. HIV vaccine design: insights from live attenuated SIV vaccines[J]. Nat Immunol, 2006, 7(1): 19-23. doi: 10.1038/ni1296
-
Letvin N L. Progress and obstacles in the development of an AIDS vaccine[J]. Nat Rev Immunol, 2006, 6(12): 930-939. doi: 10.1038/nri1959
-
Levy J A. HIV pathogenesis: knowledge gained after two decades of research[J]. Adv Dent Res, 2006, 19(1): 10-16. doi: 10.1177/154407370601900104
-
McCoy , Tatsis N, Korioth-Schmltz B. The effect of pre-existing immunity to antigens of adenovirus of the human serotype 5 on immune responses of nonhuman primates to vaccine regimens based on human or chim-panzee-derived adenovirus vectors[J]. J Virol, 2007, 81(12): 6594-6604. doi: 10.1128/JVI.02497-06
-
Papp Z, Babiuk L A, Baca-Estrada M E. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1[J]. Vaccine, 1999, 17(7-8): 933-943. doi: 10.1016/S0264-410X(98)00279-5
-
Robinson H L. New hope for AIDS vaccine[J]. Lancet, 2003, 361(9371): 1799-. doi: 10.1016/S0140-6736(03)13455-1
-
Rodriguez-Chavez I R, Allen M, Hill E L. Current advances and challenges in HIV-1 vaccines[J]. Curr HIV/AIDS Rep, 2006, 3(1): 39-47. doi: 10.1007/s11904-006-0007-0
-
Scanlan C N, Offer J, Zitzmann N, Dwek R A. Exploiting the defensive sugars of HIV-1 for drug and vaccine design[J]. Nature, 2007, 446(7139): 1038-1045. doi: 10.1038/nature05818
-
Spearman P. HIV vaccine development: lessons from the past and promise for the future[J]. Curr HIV Res, 2003, 1(1): 101-120. doi: 10.2174/1570162033352093
-
Thorner A R, Barouch D H. HIV-1 Vaccine Development: Progress and Prospects[J]. Curr Infect Dis Rep, 2007, 9(1): 71-75. doi: 10.1007/s11908-007-0025-0
-
Vanniasinkam T, Ertl H C. Adenoviral gene delivery for HIV-1 vaccination[J]. Curr Gene Ther, 2005, 5(2): 203-212. doi: 10.2174/1566523053544236
-
Veazey R S, Lackner A A. HIV swiftly guts the immune system[J]. Nat Med, 2005, 11(5): 469-470. doi: 10.1038/nm0505-469